Biocytogen is proud to be a sponsor of the 3rd annual American Society for Chinese Neuroscientists Symposium. This event is open to researchers and scientists from all levels and backgrounds, welcoming everyone to share their findings across the different areas of neuroscience. Our representative, Ruocong Tang, will be holding a talk on Genetically Modified Models to Accelerate Research and Discoveries. Don’t miss out on this wonderful opportunity for interdisciplinary collaboration!
What is the American Society for Chinese Neuroscientists Symposium?
The American Society for Chinese Neuroscientists (ASCN) Symposium is a global, non-profit organization of neuroscientists who are committed to advancing neuroscience research and developing therapeutic solutions for nervous system disorders. To learn more about ASCN, please check out their website here.
Event Overview
Date: January 28th - 30th, 2026
Reception: InterContinental Houston, Live Oak Ballroom, 6750 Main St. Houston, TX 77030
Venue: The Brown Foundation Institute of Molecular Medicine, SRB 104 Beth Robertson Auditorium, 1825 Pressler Street, Houston, TX 77030
Event Schedule
The ASCN Symposium will kick off with an 8pm reception on January 28th, 2026 at the InterContinental Houston. The next days will be filled with speaker sessions, networking opportunities, and vendor exhibits.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We are excited to meet you in Houston, TX!
